The OpenAI meltdown shows that when nonprofits and for-profits clash, the one with the money usually wins Read more
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease Read more